Phil L’Huillier is Managing Director and Chief Executive Officer (CEO) at CatalYm. He brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, …
Phil L’Huillier is Managing Director and Chief Executive Officer (CEO) at CatalYm. He brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, with an outstanding track record of success in the commercial development of businesses and partnerships.
Phil joins CatalYm from a position as Head of the European Innovation Hub & Business Development at MSD (known as Merck & Co. in North America). In this position he was an active member of MSD’s global Business Development and Licensing Leadership as well leading a team of scientific and business development professionals that executed numerous major pharmaceutical collaborations, licenses and acquisitions spanning Merck’s therapeutic areas.
Phil worked for a decade as Executive Director and Board Member of Cancer Research Technology Ltd (CRT), a leading oncology focused technology commercialization and drug discovery firm, where he was responsible for development, commercialization and licensing of numerous programs, from discovery to early clinical stages. He simultaneously played key roles in the formation of a number of biotech companies and served as Non-Executive Director for Achilles Therapeutics, Artios Pharma, BliNK Therapeutics, PsiOxus Therapeutics and Revitope Therapeutics overseeing and supporting financings and business activities. He also ran a research team for a period of five years following his PhD and Post-doctoral training. Phil holds a PhD in cellular and molecular biology from the University of Auckland, New Zealand, as well as an MBA.
Christine Schuberth-Wagner is Chief Scientific Officer (CSO) at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and …
Christine Schuberth-Wagner is Chief Scientific Officer (CSO) at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in immuno-oncology. She has established a track record as a successful leader and entrepreneur in the biotech industry.
Prior to joining CatalYm, Christine co-founded Rigontec in 2014 where she led the company’s discovery and non-clinical development activities as Senior Vice President, Research. Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100 were the basis for initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by Merck Inc. in late 2017.
Previously, Christine held research positions at the Salk Institute for Biological Studies in California, USA, and the Charité Research Organization in Berlin, Germany. She has a PhD in Molecular Biomedicine from the University of Bonn and an MBA from the University of Potsdam.
Eugen Leo is Chief Medical Officer (CMO) at CatalYm. Until late 2017, he served as CMO for Rigontec, a biotech company focused on the innate immune system …
Eugen Leo is Chief Medical Officer (CMO) at CatalYm. Until late 2017, he served as CMO for Rigontec, a biotech company focused on the innate immune system, where he helped facilitate the company’s acquisition by Merck Inc. He has more than 20 years of experience in industrial phase I-III development of targeted molecules (kinase inhibitors, antibodies, antibody derivatives, vaccines, and antisense molecules), with a focus on immuno-oncology.
Previously, he served in various positions with increasing levels of responsibility, including CMO/Vice President positions within both biotech (e.g. Micromet, ImCheck Therapeutics, Isarna Therapeutics) and large pharmaceutical companies (Johnson&Johnson, Merck-Serono). He was instrumental in reaching proof-of-concept for the BiTE (bi-specific T-cell engager) antibody platform and for the development of various other first-in-class molecules in the immuno-oncology space.
He is a board-certified Hematologist and Medical Oncologist and Associate Professor of Medicine and has spent three years as a research fellow at the Sanford-Burnham Institute, La Jolla, CA (USA), working on signal transduction and translational research in cancer. He studied medicine at the Universities of Freiburg, Münster, Heidelberg (Germany), and Cincinnati (USA) and holds an MBA from Colorado State University (USA).
Anne Burger is Chief Financial Officer (CFO) at CatalYm. She brings more than 15 years of experience in financial operations at biotech and medtech companies …
Anne Burger is Chief Financial Officer (CFO) at CatalYm. She brings more than 15 years of experience in financial operations at biotech and medtech companies throughout Europe. Currently, she also serves as the CFO and Co-Founder of Breath Therapeutics GmbH, where she was instrumental to secure the financing (EUR 43.5million) and execute the sale of the company to Zambon S.p.A. in 2019, with a deal value up to EUR 500 million.
Previously, Anne was CFO at Rigontec GmbH and had an active role in the execution of Rigontec’s trade sale to Merck Sharp & Dohme (MSD), a deal worth up to EUR 464 million. Throughout her career, Anne has been responsible for corporate fundraising, executing trade sales and licensing agreements, and preparing for IPOs in several senior executive and advisory roles in the life sciences and healthcare sectors. Anne holds a graduate degree in Business Administration from Ludwig-Maximilians-University in Munich and has completed graduate studies in public health.
Chairman of the Board of Directors
In addition to CatalYm, John is a non-executive director of Agomab (BE), Neophore (UK), Synact (SE), SynKlino (DK) and Storm (UK). Previously, John was CEO of F-star Therapeutics in Cambridge, England, and before this he was VP Research at ImClone Systems (New York), and co-founder and CSO of Symphogen, Denmark. He holds a D.Phil. in Immunology from The University of Oxford and an MD from Aarhus University, Denmark.
Dr. van Eenennaam most recently served as Chief Scientific Officer of AIMM Therapeutics and up until March 2019, Dr. van Eenennaam served as Executive Vice President of Antibody Research and Site Head for Aduro Biotech Europe. In 2015, Aduro Inc. acquired BioNovion B.V., a company advancing novel antibody therapies for Immune Oncology, which van Eenennaam co-founded in 2011, and served on in the role of Chief Operational Officer. Van Eenennaam also serves on the Board of Directors of Lygature.
At BioNovion, and later at Aduro he was involved in the discovery and development of several clinical stage antibodies: MK-5890 (anti-CD27), BION-1301 (anti-APRIL), ADU-1604 (anti-CTLA-4) and ADU-1806 (anti-SIRP).
While at Organon, Dr. van Eenennaam and colleagues discovered pembrolizumab (Keytruda®). In 2016, he was awarded the Inventor of the Year Award from the Educational Foundation of the Intellectual Property Owner Association. Dr. van Eenennaam received his doctorate (cum laude) in autoimmune biochemistry from Radboud University in Nijmegen, Netherlands.
Marc is Managing Partner, Vesalius Biocapital III. He has over 20 years of experience and joined Vesalius Biocapital in 2012 as a venture partner. Since then, Marc advised on corporate development and exit of portfolio companies of Fund 1 and Fund 2. He was promoted to Managing Partner for Fund 3 in 2017. Marc started eight lifesciences companies, i.a. co-founded Reverse Medical (acquired by Covidien in 2014), was an investment manager at Bayer Innovation and worked with several corporate finance boutiques focused on life sciences M&A transactions. Marc holds a diploma degree in business administration of the University of Stuttgart-Hohenheim (Germany).
Rogier is Partner at Forbion where he is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. He currently serves as a board member for Catalym and Achilles and as a board observer for Enterprise, Prilenia and Escalier
Prior to joining Forbion, Rogier worked as a post-doc at the Netherlands Cancer Institute (NKI), division of immunology. In 2013 he received his PhD degree Cum Laude from the University of Amsterdam for the work he performed at the NKI. Before that, he received a Master’s degree in Oncology at the VU university of Amsterdam.
Oskar joined BioGeneration as a partner in 2016 strengthening the team with his commercial, business development and consulting experience. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell first as business development director and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration he was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry.
Oskar has a degree in chemical engineering from the Twente University (NL) and holds a MBA from INSEAD.
Dr. Beat Steffen is a Principal at the Novartis Venture Fund in Basel, Switzerland. Prior to joining NVF, he worked at Novartis Pharmaceuticals in commercial roles in the US and in Switzerland launching several products mainly in the cardiovascular area. Beat joined Novartis from Wellington Partners Venture Capital where he worked with biotech and medical device startup companies. Prior to that, he was at McKinsey & Company in Zurich working with clients in the pharmaceutical industry. Beat is a Swiss-trained physician having focused in cardiovascular surgery and intensive care. He graduated from the University of Zurich Medical School and qualified as a Medical Doctor in Basel. Beat holds an MBA with distinction from INSEAD.
Nathalie is senior investment manager at Bayern Kapital, the venture capital organisation of the Free State of Bavaria. There she has worked on various projects in life science, computer science, engineering and in the energy sector. She started her career as a scientist for a biotech-start-up company in the field of drug carrier systems.
Nathalie holds a PhD in Chemistry from the Eberhard-Karl-University in Tübingen and a graduation in economics (Dipl. Wirtschafts-Chemikerin) from FernUniversität Hagen.
Professor Ralf C. Bargou is Director of the Mainfranken Comprehensive Cancer Center and Chair of the Translational Oncology Department at Wuerzburg University/Bavaria. He also serves as member of the Board of Directors of the newly formed Bavarian Cancer Research Center. He has a long-standing and successful track record for development of innovative immunotherapies for cancer and was e.g. instrumental for the preclinical, translational and clinical development of Blincyto™.
Prof. Bargou’s prime research interests are tumor immunology and cancer immunotherapy. He is author of over 130 scientific publications and has been awarded the Paul-Martini prize for outstanding pharmacological research in 2009 and the Inventor of the Year award in 2016 of the Intellectual Property Owners Education Foundation/Washington D.C..
Professor Reinhard Dummer is Professor of the University of Zürich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently, he is heading the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Prof. Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas and has published more than 741 scientific publications.
He is a founding and Board Member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and a member of the German National Academy of Sciences (Leopoldina). Prof. Dummer is a past President of the European Society for Dermatological Research (ESDR) and the International Society for Cutaneous Lymphomas. Prof. Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich, Switzerland.
Professor Alexander Eggermont is General Director of Gustave Roussy Cancer Institute, Professor of Oncology at the Paris-Sud University, and Professor of Oncological Surgery at the Erasmus University of Rotterdam in Holland. He also holds the Honorary Joseph Maisin Honorary Chair of Oncological Surgery at the Louvain Catholic University in Belgium, and an Honorary Doctorate at the University of Essen-Duisburg, Germany.
In addition, he is currently the President of the European Academy of Cancer Sciences, and the President of the Cancer Core Europe consortium. In 2015, Prof. Eggermont was elevated to the status of Chevalier of the Légion d’Honneur by the French Ministry of Foreign Affairs and International Development. His research specialty is in immunotherapy, the treatment of melanomas and sarcomas in addition to fundamental research in pathogenesis and immunology of tumors.
Professor Wolf H. Fridman is Professor Emeritus of Immunology at the Paris Descartes University Medical School in Paris, France. He received his MD and PhD degrees from the University of Paris. He has been the founder and first Director of the Cordeliers Research Centre, a joint research structure between INSERM, University Paris Descartes, and University Pierre et Marie Curie.
He was also the Head of the Immunology Laboratory of European Hospital Georges Pompidou in Paris. Prof. Fridman’s current research is focused on the immune response in the tumor microenvironment to control clinical outcomes in cervical cancer. He is a world leader in the field of human tumor immunology and has authored over 480 scientific publications in the field.
Professor Thomas Gajewski is Professor in the Departments of Pathology and Medicine at the University of Chicago. He oversees the melanoma oncology clinic and is Leader of the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center. Prof. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies, and is an author/co-author of over 270 scientific publications in the field.
He is an editor for Cancer Discovery, Journal for Experimental Medicine, and the Journal for Immunotherapy of Cancer, is on the Program Committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), and is past President of the Society for Immunotherapy of Cancer.
Dr. F. Stephen Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. His internationally recognized research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma.
Dr. Hodi is a member of ASCO, AACR, the ECOG Melanoma Committee, SITC, the European Academy of Tumor Immunology and a founding member of the Society for Melanoma Research. His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer. He published over 300 peer-reviewed scientific publications including articles in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine.
Professor Melero is Professor of Immunology at the Clinic of the University of Navarra (CUN) and at the Center for Applied Medical Research (CIMA) of the University of Navarra, Pamplona, Spain. His current areas of research are focused on translational research with cell, gene and monoclonal antibody-mediated strategies for cancer immunotherapies.
Dr. Melero has been awarded the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a Cancer Research Institute research award. He has served on the advisory boards of Bristol Myers-Squibb, Roche-Genentech, AstraZeneca, Merck Serono and Boehringer Ingelheim.
Professor Wischhusen is scientific co-founder of CatalYm. He is also the Head of the Section of Experimental Tumor Immunology at the University of Würzburg Medical School, Germany. Prof. Wischhusen’s current research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance.
Previously, he was a research group leader at the Interdisciplinary Center for Clinical Research in Würzburg. He received his PhD from the University of Tübingen, Germany in the field of molecular neuro-oncology.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.